Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

DISEASE CHARACTERISTICS: Radiographic evidence of lymphadenopathy or lymphomatous lesions combined with clinical signs of Epstein-Barr virus lymphoproliferative disease (EBV LPD), such as fevers and lymphadenopathy, following an organ transplant Persistent, progressive, or unresponsive disease despite decreased immunosuppression, chemotherapy, or radiation therapy EBV LPD must be of host orgin

PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified Life expectancy: At least 4 weeks Hematopoietic: Not specified Hepatic: Patients serologically hepatitis B and C positive may receive cytotoxic T lymphocytes (CTL) from donors who are serologically positive for the same virus No hepatic dysfunction SGOT/SGPT less than 2.5 times upper limit of normal (unless liver metastases present) Bilirubin less than 2.0 mg/dL Renal: No renal dysfunction Creatinine clearance at least 50 mL/min Cardiovascular: No cardiac dysfunction Neurologic: No neurologic dysfunction Pulmonary: No pulmonary dysfunction Other: (patient) Must have an HLA identical or HLA haploidentical donor No patients developing EBV LPD who have a donor origin lymphoma Patients serologically positive for cytomegalovirus positive may receive CTL from donors who are serologically positive for the same virus (donor) Not HIV-1 positive Medically fit to undergo leukapheresis Donor CTL must be capable of lysing patient B lymphoblastoid cell line (BLCL) in vitro

PRIOR CONCURRENT THERAPY: Not specified